SG11202111131VA - Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations - Google Patents
Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrationsInfo
- Publication number
- SG11202111131VA SG11202111131VA SG11202111131VA SG11202111131VA SG11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA
- Authority
- SG
- Singapore
- Prior art keywords
- amorphous solid
- plasma concentrations
- enhanced performance
- therapeutic plasma
- achieving therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962832606P | 2019-04-11 | 2019-04-11 | |
PCT/US2020/027677 WO2020210629A1 (en) | 2019-04-11 | 2020-04-10 | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111131VA true SG11202111131VA (en) | 2021-11-29 |
Family
ID=70465560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111131VA SG11202111131VA (en) | 2019-04-11 | 2020-04-10 | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations |
Country Status (18)
Country | Link |
---|---|
US (1) | US20220144835A1 (en) |
EP (1) | EP3953355A1 (en) |
JP (1) | JP2022526656A (en) |
KR (1) | KR20210151183A (en) |
CN (1) | CN113924300A (en) |
AR (1) | AR118650A1 (en) |
AU (1) | AU2020271103A1 (en) |
BR (1) | BR112021020257A2 (en) |
CA (1) | CA3132530A1 (en) |
CL (1) | CL2021002627A1 (en) |
CO (1) | CO2021015054A2 (en) |
EA (1) | EA202192753A1 (en) |
IL (1) | IL287103A (en) |
MX (1) | MX2021012288A (en) |
PE (1) | PE20212367A1 (en) |
SG (1) | SG11202111131VA (en) |
TW (1) | TW202104228A (en) |
WO (1) | WO2020210629A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2024508970A (en) | 2021-03-09 | 2024-02-28 | バイエル・アクチエンゲゼルシヤフト | (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridina-1 (1) - Pharmaceutical dosage form containing [1,2,3] triazola-2(1,2),7(1)-dibenzenaheptaphan-74-carboxamide |
WO2023043999A1 (en) | 2021-09-17 | 2023-03-23 | Bristol-Myers Squibb Company | Milvexian for prevention and treatment of thromboembolic disorders |
WO2024030409A1 (en) | 2022-08-01 | 2024-02-08 | Bristol-Myers Squibb Company | Use of milvexian for treating or preventing ischemic stroke |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI864812A (en) | 1985-11-27 | 1987-05-28 | Syntex Inc | FOERFARANDE FOER FRAMSTAELLNING AV AMORFA BENSIMIDAZOLDERIVAT. |
DK0901786T3 (en) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Solid pharmaceutical dispersions with increased bioavailability |
WO2010102245A1 (en) | 2009-03-05 | 2010-09-10 | Upsher-Smith Laboratories, Inc. | Solid dispersion comprising resveratrol |
JP6464176B2 (en) * | 2014-01-31 | 2019-02-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Macrocycles as factor XIA inhibitors with aromatic P2 'groups |
NO2721243T3 (en) * | 2014-10-01 | 2018-10-20 | ||
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
-
2020
- 2020-04-10 WO PCT/US2020/027677 patent/WO2020210629A1/en unknown
- 2020-04-10 EP EP20722195.3A patent/EP3953355A1/en active Pending
- 2020-04-10 US US17/602,025 patent/US20220144835A1/en active Pending
- 2020-04-10 CA CA3132530A patent/CA3132530A1/en active Pending
- 2020-04-10 JP JP2021559853A patent/JP2022526656A/en active Pending
- 2020-04-10 MX MX2021012288A patent/MX2021012288A/en unknown
- 2020-04-10 CN CN202080041944.7A patent/CN113924300A/en active Pending
- 2020-04-10 BR BR112021020257A patent/BR112021020257A2/en unknown
- 2020-04-10 PE PE2021001691A patent/PE20212367A1/en unknown
- 2020-04-10 AU AU2020271103A patent/AU2020271103A1/en active Pending
- 2020-04-10 SG SG11202111131VA patent/SG11202111131VA/en unknown
- 2020-04-10 TW TW109112257A patent/TW202104228A/en unknown
- 2020-04-10 EA EA202192753A patent/EA202192753A1/en unknown
- 2020-04-10 KR KR1020217036797A patent/KR20210151183A/en active Search and Examination
- 2020-04-13 AR ARP200101025A patent/AR118650A1/en unknown
-
2021
- 2021-10-07 CL CL2021002627A patent/CL2021002627A1/en unknown
- 2021-10-07 IL IL287103A patent/IL287103A/en unknown
- 2021-11-08 CO CONC2021/0015054A patent/CO2021015054A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL287103A (en) | 2021-12-01 |
BR112021020257A2 (en) | 2021-12-07 |
US20220144835A1 (en) | 2022-05-12 |
MX2021012288A (en) | 2021-11-12 |
EP3953355A1 (en) | 2022-02-16 |
EA202192753A1 (en) | 2022-01-11 |
JP2022526656A (en) | 2022-05-25 |
CN113924300A (en) | 2022-01-11 |
KR20210151183A (en) | 2021-12-13 |
PE20212367A1 (en) | 2021-12-21 |
AU2020271103A1 (en) | 2021-12-02 |
AR118650A1 (en) | 2021-10-20 |
TW202104228A (en) | 2021-02-01 |
CL2021002627A1 (en) | 2022-05-06 |
WO2020210629A1 (en) | 2020-10-15 |
CO2021015054A2 (en) | 2021-11-19 |
CA3132530A1 (en) | 2020-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287103A (en) | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations | |
EP3407918A4 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
EP3356521A4 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
EP3302709A4 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
EP3920923A4 (en) | Therapeutic agents and methods of treatment | |
MX353762B (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation. | |
MX348726B (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation. | |
IN2013MU01696A (en) | ||
EP4058190A4 (en) | Compositions and methods for controlled delivery and protection of therapeutic agents | |
EP4003401A4 (en) | Compositions and methods comprising protease-activated therapeutic agents | |
EP3890747A4 (en) | Compositions for the treatment of fibrosis and inflammation | |
EP3860621A4 (en) | Iron formulations for topical administration and methods of treatment of iron deficiency | |
IL287260A (en) | Compositions and methods for treatment of cystic fibrosis | |
EP3500291A4 (en) | Formulations for oral administration of active agents | |
EP3969597A4 (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
EP3856172A4 (en) | Pharmaceutically active cannabis-based compositions and methods of use for treating gastrointestinal conditions | |
EP3952881A4 (en) | Compositions and methods for the treatment of contact lens discomfort | |
EP3917910A4 (en) | Therapeutic compounds and compositions | |
IL289786A (en) | Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof | |
IL277913A (en) | Topical formulations comprising strontium and methylsulfonylmethane (msm) and niethods of treatment | |
EP4017873A4 (en) | Compositions and methods for the treatment of pathological pain and itch | |
EP3810647A4 (en) | Methods and compositions for treatment of hemophilia | |
EP3694517A4 (en) | Compositions and methods for treatment of fibrosis | |
IL289236A (en) | Compositions and methods for treatment of fungal infections | |
EP3468540A4 (en) | Pharmaceutical compositions and methods for treatment of pain |